Incidence , Clinical Features , and Outcome of All Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

@inproceedings{Botton1998IncidenceC,
  title={Incidence , Clinical Features , and Outcome of All Trans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia},
  author={St{\'e}phane de Botton and Herv{\'e} Dombret and Marta Sanz and Jes{\'u}s San Miguel and Denis Caillot and Robert Zittoun and Martine Gardembas and Aspasia Stamatoulas and Esther Conde and Aline Guerci and Claude Gardin and Kenneth Geiser and D. Cony Makhoul and Oum{\'e}daly Reman and J P{\'e}rez de la Serna and François Lefr{\`e}re and Christine Chomienne and Cl. Chastang and Laurent Degos and Pierre Fenaux},
  year={1998}
}
All trans-retinoic acid (ATRA) syndrome is a life-threatening complication of uncertain pathogenesis that can occur during the treatment of acute promyelocytic leukemia (APL) by ATRA. Since its initial description, however, no large series of ATRA syndrome has been reported in detail. We analyzed cases of ATRA syndrome observed in an ongoing European trial… CONTINUE READING